FAQ

FAQ published on March 21, 2014
Dr. Borchmann discusses the efficacy and safety of long-term treatment that includes involved field radiotherapy.
FAQ published on March 5, 2014
Dr. Engert discusses the treatment regimen BEACOPP escalated and the occurrence of acute leukemia and myelodysplasia after treatment.
FAQ published on March 5, 2014
Dr. Hutchings discusses the role of PET-CT for therapy in patients with relapsed/refractory Hodgkin lymphoma.
FAQ published on March 5, 2014
Dr. Andrew Zelenetz discusses the appropriateness of nonmyeloablative allogeneic SCT in the treatment patients with refractory Hodgkin lymphoma.
FAQ published on February 12, 2014
Dr. Federico discusses measuring tumor burden in Hodgkin lymphoma patients.
FAQ published on February 12, 2014
Dr. Andrew Evens discusses treatment options and specific risk factors associated with the elderly patient.
FAQ published on February 12, 2014
Dr. Steidl discusses the difference between prognostic and predictive biomarkers and the value of each to clinical practice.
FAQ published on February 4, 2014
Dr. Borchmann discusses the risks associated with BEACOPP escalated in advanced-stage Hodgkin lymphoma.
FAQ published on February 4, 2014
Dr. Hutchings discusses the results of the International Confirmatory Study, the significance of the study, and how is translates to clinical practice.
FAQ published on January 15, 2014
Dr. Engert discusses the currently available treatment guidelines for the treatment of Hodgkin lymphoma patients.
Page 5 of 6
Results 41 - 50 of 58

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved